prikaz prve stranice dokumenta Liječenje uznapredovalih karcinoma pločastih stanica kože
  Download
PDF 736.93 KB
master's thesis
Liječenje uznapredovalih karcinoma pločastih stanica kože
Zagreb: University of Zagreb, School of Medicine, 2022. urn:nbn:hr:105:861103
Čičak, Lara
University of Zagreb
School of Medicine
Department of Clinical Oncology

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Čičak, L. (2022). Liječenje uznapredovalih karcinoma pločastih stanica kože (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:861103

Čičak, Lara. "Liječenje uznapredovalih karcinoma pločastih stanica kože." Master's thesis, University of Zagreb, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:105:861103

Čičak, Lara. "Liječenje uznapredovalih karcinoma pločastih stanica kože." Master's thesis, University of Zagreb, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:105:861103

Čičak, L. (2022). 'Liječenje uznapredovalih karcinoma pločastih stanica kože', Master's thesis, University of Zagreb, School of Medicine, accessed 02 May 2024, https://urn.nsk.hr/urn:nbn:hr:105:861103

Čičak L. Liječenje uznapredovalih karcinoma pločastih stanica kože [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2022 [cited 2024 May 02] Available at: https://urn.nsk.hr/urn:nbn:hr:105:861103

L. Čičak, "Liječenje uznapredovalih karcinoma pločastih stanica kože", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:105:861103

Metadata
TitleLiječenje uznapredovalih karcinoma pločastih stanica kože
Title (english)Treatment of advanced cutaneous squamous cell carcinoma
AuthorLara Čičak
MentorJasmina Marić Brozić (mentor)
Committee memberMarija Gamulin (predsjednik povjerenstva)
Committee memberLidija Beketić-Orešković (član povjerenstva)
Committee memberJasmina Marić Brozić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Clinical Oncology)
Zagreb
Defense date and country2022-07-15, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract
Karcinom pločastih stanica kože (engl. cutaneous squamous cell carcinoma - cSCC) nemelanomski je tumor kože koji nastaje malignom alteracijom keratinocita. Predstavlja jedan od najčešćih tumora u bijeloj populaciji s rastućom incidencijom. Među najznačajnijim čimbenicima rizika za razvoj cSCC nalaze se izloženost ultraljubičastom zračenju, starija životna dob, svijetla put i imunosupresija. Jedan dio cSCC pokazuje agresivniji tijek bolesti sa sklonošću recidiviranja i metastaziranja. Uznapredovali cSCC obuhvaća lokalno uznapredovali cSCC i metastatski cSCC s regionalnim ili udaljenim metastazama. Stratifikacija cSCC u skupinu niskog ili visokog rizika za lošijim kliničkim ishodom preporuča se na temelju čimbenika visokog rizika. Danas korišteni klasifikacijski sustavi za određivanje stadija cSCC uključuju sustav 8. izdanja priručnika Američkog društva za rak, sustav 8. izdanja priručnika Unije za međunarodnu kontrolu raka i „Brigham and Women’s Hospital“ klasifikacijski sustav. Kirurška ekscizija prvi je terapijski izbor za liječenje cSCC. Bolje razumijevanje molekularne patogeneze u nastanku cSCC dovelo je do otkrića novih terapijskih opcija za sustavno liječenje uznapredovalog karcinoma. Ono uključuje ciljanu terapiju inhibitorima receptora epidermalnog faktora rasta i imunoterapiju inhibitorima proteina programirane stanične smrti-1. Cemiplimab, prvi registrirani lijek za liječenje uznapredovalog cSCC, promijenio je terapijske ishode oboljelih te pokrenuo novi val istraživanja u liječenju uznapredovalog oblika bolesti.
Abstract (english)
Cutaneous squamous cell carcinoma is a nonmelanoma skin cancer caused by malignant alteration of keratinocytes. It represents one of the most common tumors in the white population with a growing incidence. The most common factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure, older age, fair skin and immunosuppression. A subset of cSCC shows a more aggressive course with a tendency to recur and metastasize. Advanced cSCC is classified as locally advanced cSCC and metastatic cSCC including regional or distant metastases. Stratification of cSCC into a low risk or high risk group for a poor clinical outcome is recommended based on high risk factors. Current systems used for staging include the American Joint Committee on Cancer 8th edition, the Union for International Cancer Control 8th edition and Brigham and Women’s Hospital system. Surgical excision is the first-line treatment for cSCC. A better understanding of the molecular pathogenesis in the development of cSCC has led to the discovery of new therapeutic options for the systemic treatment of advanced cSCC. Epidermal growth factor receptor targeted treatments and programmed cell death-1 protein immune checkpoint inhibitors have been added in the therapeutic landscape of advanced cSCC. Cemiplimab, the first registered drug for the treatment of advanced cSCC, has altered the therapeutic outcomes of cSCC patients and launched a new wave of research in the treatment of advanced disease.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:861103
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2023-01-05 07:59:53